Advances in treatment formulations for acute myeloid leukemia

Abstract : Acute myeloid leukemia (AML) is the most common cause of leukemia-related mortality. The combination of cytarabine and anthracycline has been the gold standard of treatment over the past 40 years, but the distribution of the drugs in the body leads to severe adverse effects. Poor prognosis of older patients with AML is the consequence not only of comorbidities, but also of chemoresistance resulting from frequent secondary AML. Numerous strategies using nanotechnologies are in development to improve drug targeting, pharmacokinetics, administration route, chemoresistance, and adverse effects generally observed. Among the four new drugs approved for AML by the US Food and Drug Administration (FDA) in 2017, Vyxeos® is a novel liposomal formulation of historical AML drugs. Here, we review current AML treatments and discuss how the development of new formulations will change the therapeutic armamentarium.
Document type :
Journal articles
Complete list of metadatas

Cited literature [118 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01809889
Contributor : Elizabeth Bernardo <>
Submitted on : Thursday, June 7, 2018 - 11:45:37 AM
Last modification on : Friday, October 4, 2019 - 1:49:48 AM

File

ArticlemainEqAngers.pdf
Files produced by the author(s)

Identifiers

Citation

Thomas Briot, Emilie Roger, Sylvain Thépot, Frédéric Lagarce. Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today Biosilico, Elsevier, 2018, Epub ahead of print. ⟨10.1016/j.drudis.2018.05.040⟩. ⟨inserm-01809889⟩

Share

Metrics

Record views

242

Files downloads

383